Charles Schwab Investment Management Inc. Raises Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Charles Schwab Investment Management Inc. increased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 16.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,404,883 shares of the company’s stock after purchasing an additional 202,863 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Amneal Pharmaceuticals were worth $11,689,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Hennessy Advisors Inc. purchased a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth $8,818,000. Rubric Capital Management LP raised its holdings in shares of Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after purchasing an additional 1,179,830 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after purchasing an additional 710,598 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Amneal Pharmaceuticals by 114.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock worth $10,026,000 after purchasing an additional 642,065 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Amneal Pharmaceuticals by 17.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after purchasing an additional 641,405 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 26.56% of the stock is owned by insiders.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $8.45 on Monday. Amneal Pharmaceuticals, Inc. has a 12 month low of $4.46 and a 12 month high of $9.48. The company’s fifty day moving average price is $8.55 and its two-hundred day moving average price is $7.86. The firm has a market capitalization of $2.62 billion, a P/E ratio of -12.43 and a beta of 1.12.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AMRX. StockNews.com raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 11th. Piper Sandler lifted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Truist Financial increased their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective on the stock in a research note on Friday, September 6th. Finally, Barclays upped their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.